 The purpose of Study GS-01-934 was to assess the efficacy and safety of two simplified antiretroviral treatment ART regimens in ART-naive, human immunodeficiency virus, type 1 HIV-1 infected participants. The primary objective of the study was to assess noninferiority of emtricitabine FTC and tenofovir disoproxil fumarate tenofovir DF; TDF in combination with efavirenz EFV relative to Combivir CBV in combination with EFV in the treatment of HIV-1 infected ART-naive participants, determined by the achievement and maintenance of confirmed HIV-1 ribonucleic acid RNA 400 copiesmL cmL through Week 48, as defined by the United States US Food and Drug Administration FDA time-to-loss-of-virologic-response TLOVR algorithm. 